1. Home
  2. PRTC vs SMBK Comparison

PRTC vs SMBK Comparison

Compare PRTC & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • SMBK
  • Stock Information
  • Founded
  • PRTC 2015
  • SMBK N/A
  • Country
  • PRTC United States
  • SMBK United States
  • Employees
  • PRTC N/A
  • SMBK N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • SMBK Major Banks
  • Sector
  • PRTC Health Care
  • SMBK Finance
  • Exchange
  • PRTC Nasdaq
  • SMBK Nasdaq
  • Market Cap
  • PRTC 439.8M
  • SMBK 521.4M
  • IPO Year
  • PRTC N/A
  • SMBK N/A
  • Fundamental
  • Price
  • PRTC $17.90
  • SMBK $31.56
  • Analyst Decision
  • PRTC Buy
  • SMBK Buy
  • Analyst Count
  • PRTC 1
  • SMBK 5
  • Target Price
  • PRTC $45.00
  • SMBK $34.40
  • AVG Volume (30 Days)
  • PRTC 2.0K
  • SMBK 60.4K
  • Earning Date
  • PRTC 04-30-2025
  • SMBK 07-21-2025
  • Dividend Yield
  • PRTC N/A
  • SMBK 1.01%
  • EPS Growth
  • PRTC N/A
  • SMBK 44.84
  • EPS
  • PRTC 0.21
  • SMBK 2.26
  • Revenue
  • PRTC $4,828,000.00
  • SMBK $171,664,000.00
  • Revenue This Year
  • PRTC $35.98
  • SMBK $20.95
  • Revenue Next Year
  • PRTC $115.38
  • SMBK $9.48
  • P/E Ratio
  • PRTC $7.81
  • SMBK $13.99
  • Revenue Growth
  • PRTC 44.98
  • SMBK 16.34
  • 52 Week Low
  • PRTC $13.30
  • SMBK $21.56
  • 52 Week High
  • PRTC $28.39
  • SMBK $37.72
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 46.07
  • SMBK 49.38
  • Support Level
  • PRTC $19.00
  • SMBK $30.95
  • Resistance Level
  • PRTC $19.80
  • SMBK $32.97
  • Average True Range (ATR)
  • PRTC 0.33
  • SMBK 0.67
  • MACD
  • PRTC -0.12
  • SMBK -0.13
  • Stochastic Oscillator
  • PRTC 16.30
  • SMBK 30.05

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

Share on Social Networks: